FDA Signals Interest In Requiring Unique Biosimilar Names

OND Director Jenkins expresses concern at a public hearing that the agency could miss or confuse some spontaneous adverse events if biosimilars are not distinguished from their reference product.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet